Trial Outcomes & Findings for Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia (NCT NCT01620216)

NCT ID: NCT01620216

Last Updated: 2021-11-04

Results Overview

Will be defined as defined as a decrease of at least 25% in bone marrow blast counts or peripheral blood blast. The proportion of patients achieving the endpoint along with its 95% exact binomial confidence interval will be presented.

• Recruitment status: TERMINATED
• Study phase: PHASE2
• Target enrollment: 12 participants
• Primary outcome timeframe: Up to 28 days
• Results posted on: 2021-11-04

Participant Flow

Participant milestones

Measure	Group I (Dasatinib) Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Group II (Sutinib Malate) Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO	Group III (Sorafenib Tosylate) Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO	Group IV (Ponatinib Hydrochloride) Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO	Group V (Pacritinib) Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies	Group VI (Ruxolitinib) Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO	Group VII (Idelalisib) Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies
Overall Study STARTED	4	2	6	0	0	0	0
Overall Study COMPLETED	4	2	6	0	0	0	0
Overall Study NOT COMPLETED	0	0	0	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Baseline characteristics by cohort

Measure	Group I (Dasatinib) n=4 Participants Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Group II (Sutinib Malate) n=2 Participants Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO	Group III (Sorafenib Tosylate) n=6 Participants Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO	Group IV (Ponatinib Hydrochloride) Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO	Group V (Pacritinib) Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies	Group VI (Ruxolitinib) Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO	Group VII (Idelalisib) Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Total n=12 Participants Total of all reporting groups
Age, Continuous	70.5 Years n=5 Participants	50 Years n=7 Participants	57.5 Years n=5 Participants	—	—	—	—	63 Years n=24 Participants
Sex: Female, Male Female	1 Participants n=5 Participants	1 Participants n=7 Participants	5 Participants n=5 Participants	—	—	—	—	7 Participants n=24 Participants
Sex: Female, Male Male	3 Participants n=5 Participants	1 Participants n=7 Participants	1 Participants n=5 Participants	—	—	—	—	5 Participants n=24 Participants
Race/Ethnicity, Customized Race/Ethnicity · White	3 Participants n=5 Participants	2 Participants n=7 Participants	4 Participants n=5 Participants	—	—	—	—	9 Participants n=24 Participants
Race/Ethnicity, Customized Race/Ethnicity · Hispanic or Latino	1 Participants n=5 Participants	0 Participants n=7 Participants	2 Participants n=5 Participants	—	—	—	—	3 Participants n=24 Participants

PRIMARY outcome

Timeframe: Up to 28 days

Population: Zero patients enrolled in Ponatinib, Pacrtitinib, Ruxolitinib, and Idealisib arms.

Will be defined as defined as a decrease of at least 25% in bone marrow blast counts or peripheral blood blast. The proportion of patients achieving the endpoint along with its 95% exact binomial confidence interval will be presented.

Outcome measures

Measure	Group I (Dasatinib) n=4 Participants Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Group II (Sutinib Malate) n=2 Participants Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO	Group III (Sorafenib Tosylate) n=6 Participants Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO	Group IV (Ponatinib Hydrochloride) Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO	Group V (Pacritinib) Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies	Group VI (Ruxolitinib) Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO	Group VII (Idelalisib) Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies
Clinical Activity	1 Participants	0 Participants	4 Participants	—	—	—	—

SECONDARY outcome

Timeframe: Up to 3 years

Population: Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.

Per Response Evaluation Criteria in AML or ALL: Complete Response (CR), at least <5% bone marrow blasts; Partial Response (PR), reduction of >=50% bone marrow blasts; Overall Response (OR)= CR + PR.

The proportion of patients achieving the endpoint along with its 95% exact binomial confidence interval will be presented.

Outcome measures

Measure	Group I (Dasatinib) n=4 Participants Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Group II (Sutinib Malate) n=2 Participants Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO	Group III (Sorafenib Tosylate) n=6 Participants Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO	Group IV (Ponatinib Hydrochloride) Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO	Group V (Pacritinib) Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies	Group VI (Ruxolitinib) Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO	Group VII (Idelalisib) Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies
Overall Objective Response Rates (Complete and Partial) Partial response	0 Participants	0 Participants	1 Participants	—	—	—	—
Overall Objective Response Rates (Complete and Partial) Progressive disease	2 Participants	0 Participants	0 Participants	—	—	—	—
Overall Objective Response Rates (Complete and Partial) Stable disease	2 Participants	2 Participants	4 Participants	—	—	—	—
Overall Objective Response Rates (Complete and Partial) Not assessable	0 Participants	0 Participants	1 Participants	—	—	—	—

SECONDARY outcome

Timeframe: From the start of study drug treatment to death, regardless of cause of death, or date of disease progression defined as a >= 50% increase in leukemic bone marrow blasts, whichever occurs first, assessed up to 3 years

Population: Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.

Kaplan-Meier method will be used to estimate the survival curve.

Outcome measures

Measure	Group I (Dasatinib) n=4 Participants Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Group II (Sutinib Malate) n=2 Participants Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO	Group III (Sorafenib Tosylate) n=6 Participants Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO	Group IV (Ponatinib Hydrochloride) Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO	Group V (Pacritinib) Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies	Group VI (Ruxolitinib) Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO	Group VII (Idelalisib) Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies
Progression-free Survival	1 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: From the date of subject registration to death, regardless of causes of death, assessed up to 3 years

Population: Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.

Kaplan-Meier method will be used to estimate the survival curve.

Outcome measures

Measure	Group I (Dasatinib) n=4 Participants Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Group II (Sutinib Malate) n=2 Participants Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO	Group III (Sorafenib Tosylate) n=6 Participants Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO	Group IV (Ponatinib Hydrochloride) Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO	Group V (Pacritinib) Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies	Group VI (Ruxolitinib) Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO	Group VII (Idelalisib) Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies
Overall Survival	57 Days Interval 18.0 to 147.0	75 Days Interval 6.0 to 144.0	130 Days Interval 43.0 to 430.0	—	—	—	—

SECONDARY outcome

Timeframe: Up to 28 days

Population: Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.

Will be defined as a decrease of at least 25% in bone marrow blast counts or in peripheral blood blasts in subjects who have failed the initial inhibitor but are then treated with another inhibitor identified on repeat pre-clinical activity testing. The proportion of patients achieving the endpoint along with its 95% exact binomial confidence interval will be presented.

Outcome measures

Measure	Group I (Dasatinib) n=4 Participants Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Group II (Sutinib Malate) n=2 Participants Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO	Group III (Sorafenib Tosylate) n=6 Participants Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO	Group IV (Ponatinib Hydrochloride) Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO	Group V (Pacritinib) Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies	Group VI (Ruxolitinib) Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO	Group VII (Idelalisib) Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies
Clinical Activity	0 Participants	0 Participants	0 Participants	—	—	—	—

OTHER_PRE_SPECIFIED outcome

Timeframe: Up to 3 years

Population: Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.

Presence of active/aberrant kinase pathways will be determined using a small molecule kinase inhibitor screen, to rapidly identify therapeutic tyrosine kinase targets in leukemia patients while simultaneously providing individualized therapeutic options. Will be correlated with treatment response, mutational analysis using next generation sequencing, and characterization of aberrant gene expression in primary leukemia samples.

Outcome measures

Measure	Group I (Dasatinib) n=4 Participants Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Group II (Sutinib Malate) n=2 Participants Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO	Group III (Sorafenib Tosylate) n=6 Participants Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO	Group IV (Ponatinib Hydrochloride) Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO	Group V (Pacritinib) Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies	Group VI (Ruxolitinib) Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO	Group VII (Idelalisib) Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies
Presence of Active/Aberrant Kinase Pathways	4 Participants	2 Participants	6 Participants	0 Participants	0 Participants	0 Participants	0 Participants

Adverse Events

Group I (Dasatinib)

Serious events: 2 serious events

Other events: 3 other events

Deaths: 0 deaths

Group II (Sunitinib Malate)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Group III (Sorafenib Tosylate)

Serious events: 5 serious events

Other events: 6 other events

Deaths: 0 deaths

Group IV (Ponatinib Hydrochloride)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Group V (Pacritinib)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Group VI (Ruxolitinib)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Group VII (Idelalisib)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Measure	Group I (Dasatinib) n=4 participants at risk Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Group II (Sunitinib Malate) n=2 participants at risk Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO	Group III (Sorafenib Tosylate) n=6 participants at risk Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO	Group IV (Ponatinib Hydrochloride) Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO	Group V (Pacritinib) Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies	Group VI (Ruxolitinib) Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO	Group VII (Idelalisib) Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies
Respiratory, thoracic and mediastinal disorders Hypoxia	50.0% 2/4 • Number of events 2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Respiratory, thoracic and mediastinal disorders Lung infection	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Musculoskeletal and connective tissue disorders Myositis	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Infections and infestations Tooth infection	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Investigations Febrile neutropenia	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	66.7% 4/6 • Number of events 5 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Metabolism and nutrition disorders Hypoalbumenia	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Metabolism and nutrition disorders Lipase increased	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Respiratory, thoracic and mediastinal disorders Pleural effusion	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Infections and infestations Sepsis	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.

Other adverse events

Measure	Group I (Dasatinib) n=4 participants at risk Patients receive dasatinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Dasatinib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies	Group II (Sunitinib Malate) n=2 participants at risk Patients receive sutinib malate PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sunitinib: Given PO Sunitinib Malate: Given PO	Group III (Sorafenib Tosylate) n=6 participants at risk Patients receive sorafenib tosylate PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Sorafenib: Given PO Sorafenib Tosylate: Given PO	Group IV (Ponatinib Hydrochloride) Patients receive ponatinib hydrochloride PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ponatinib: Given PO Ponatinib Hydrochloride: Given PO	Group V (Pacritinib) Patients receive pacritinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pacritinib: Given PO Pharmacological Study: Correlative studies	Group VI (Ruxolitinib) Patients receive ruxolitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies Ruxolitinib: Given PO	Group VII (Idelalisib) Patients receive idelalisib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Antitumor Drug Screening Assay: Undergo pre clinical kinase inhibitor activity screening Idelalisib: Given PO Laboratory Biomarker Analysis: Correlative studies Pharmacological Study: Correlative studies
Renal and urinary disorders Acute kidney injury	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Metabolism and nutrition disorders Alanine aminotransferase increased	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Blood and lymphatic system disorders Anemia	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	33.3% 2/6 • Number of events 2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Immune system disorders Arthritis	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Blood and lymphatic system disorders Hyperleukocytosis	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Blood and lymphatic system disorders Blood bilirubin increased	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Respiratory, thoracic and mediastinal disorders Bronchial infection	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Cardiac disorders Short of breath	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Cardiac disorders Tachycardia	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Cardiac disorders Troponemia	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Metabolism and nutrition disorders Creatinine increased	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Gastrointestinal disorders Diarrhea	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Cardiac disorders Dyspnea	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Endocrine disorders Elevated LFTs	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Cardiac disorders Hypertension	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Metabolism and nutrition disorders Hyperuricemia	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Metabolism and nutrition disorders Hypoalbuminemia	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Metabolism and nutrition disorders Hypophosphatemia	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Infections and infestations Influenza	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Respiratory, thoracic and mediastinal disorders Lung infection	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	33.3% 2/6 • Number of events 2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Musculoskeletal and connective tissue disorders Myositis	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Gastrointestinal disorders Nausea	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Blood and lymphatic system disorders Neutrophil count decreased	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	33.3% 2/6 • Number of events 2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Blood and lymphatic system disorders Platelet count decreased	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	33.3% 2/6 • Number of events 2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Respiratory, thoracic and mediastinal disorders Pneumonitis	25.0% 1/4 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/6 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Gastrointestinal disorders Vomiting	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.
Blood and lymphatic system disorders White blood cell decreased	0.00% 0/4 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	0.00% 0/2 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	16.7% 1/6 • Number of events 1 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.	— 0/0 • Adverse event collection began on the first day of the start of the induction chemotherapy and continued until 30 days post last dose of study drug. Zero patients enrolled in Ponatinib, Pacritinib, Ruxolitinib, and Idealisib arms.

Additional Information

Dr. Stephen Spurgeon

OHSU

Phone: 5034948950

Email: spurgeos@ohsu.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place